Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines.
about
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesPre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responsesAvian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetEgg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesA human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primatesImmunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunityInduction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells.Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.Wound Healing Versus Regeneration: Role of the Tissue Environment in Regenerative Medicine.CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individualsThe role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trialDNA vaccines against human immunodeficiency virus type 1 in the past decade.Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses.Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's diseaseAdenovirus as vehicle for anticancer genetic immunotherapy.Development of nonhuman adenoviruses as vaccine vectors.Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.Intranasal delivery of vaccines against HIV.Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination.Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitopeA fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41Technical transformation of biodefense vaccines.Current progress of DNA vaccine studies in humans.Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors.Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.Heterologous prime-boost vaccination.Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity.Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.DNA vaccines for targeting bacterial infections.Residual DNA analysis in biologics development: review of measurement and quantitation technologies and future directions.Therapeutic live vaccines as a potential anticancer strategy.Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.
P2860
Q21089693-F38E64BB-D0AF-453D-A027-AA16DB9FC766Q27013568-037D0EF0-5394-4B1E-A106-2B81D3DD490DQ27304910-B7D9C388-E58F-4A90-9B7C-FF9021645221Q30227194-C97441B8-160E-43D8-AD66-C4CE8FFE8334Q30382097-A59FF53C-7883-4A52-ADC0-7022533E46DAQ33780685-7F98C9AB-5BFA-4F14-973B-44323B862BC4Q33883854-54A18DCC-DD94-479C-AF3C-1DD8A06B9B31Q33908767-7A5299FA-758B-4A90-BFF3-C1FD53822CC3Q34033557-8AAAF4AA-910B-4187-AD25-C8C3EC0FC0F4Q34120270-B958B2F5-2940-4944-BE19-9C514C078A50Q34309830-E6F750A5-C5C2-44CB-BAC7-69D0CAD1DF96Q34353428-F44ED5D8-D3DE-4F85-B4EC-C64A81CC10CAQ34385682-72222034-4B1B-4997-9521-8963B355A42DQ34692141-E317D8E8-6560-462D-B5AC-D252B1DB8E54Q35496004-832AAE27-34AF-4D1A-ACC0-3E20B64896DDQ35745831-92138E25-12B7-4D98-A8EA-C66ADFE1B301Q35826378-C5E9644E-50C0-4AAC-A1BE-CF35CDB3CA68Q35951849-78D4395F-430F-4585-B72B-2698671A7779Q36026890-322E6D70-568A-488C-8F3E-302056A1E9ABQ36288930-8B2F82C5-7C33-4B9D-AF0D-FE6295917E1BQ36317264-4223B916-3DF5-4333-9A9D-DDDD6754D3FFQ36373305-68AA1DE0-CB44-4FBF-B321-ACBE3C3BD1C4Q36409054-93A17855-7AAD-4B01-9CEB-972EFE6E8FC1Q36474557-ED0369F7-7184-4193-B582-0B675C24D148Q36539553-26CEB3B2-1B29-4E97-836F-9E00F3D2C8D7Q36627951-DCCE1C6A-EA42-4A34-96AA-AC17E57F46CFQ36824066-895246F8-51D8-4AC5-A756-4A47CD4B515FQ36976598-8236CA3A-5087-42B1-A97E-466B89E2F31EQ37058898-46CF8E45-7490-41C0-BEBE-1B5AE41C0BE1Q37103923-39C4A7CD-92AF-457F-A60F-2B2B93EC2D0AQ37348513-D7311306-B62B-4393-81D4-9EC5627E85AAQ37355936-0E51FA41-6714-4E96-AA96-B9F0DB319AD4Q37509586-99745AC2-4F0D-426E-B362-8BF7A8EEEB59Q37590335-779C9F9E-FBA3-4AF1-B958-7A6B2ADDB8A9Q37596543-D6DBD4EA-72D5-4BF2-8B76-9840B9A7DFDDQ37713960-F191C905-7643-4FC7-BF7E-F8A6219BDDC5Q37771943-99EA52C1-02B9-4D65-8D0F-5D78EE9E549CQ37940194-8F601CEC-E1CC-435C-80C6-4EC017D3C3B4Q38011653-58BF4026-7762-406D-8A79-48347B951550Q38284700-2F8C2E01-FC37-4E8E-98CC-A7C4E58AE5E6
P2860
Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Plasmid chemokines and colony- ...... iciency virus type 1 vaccines.
@ast
Plasmid chemokines and colony- ...... iciency virus type 1 vaccines.
@en
type
label
Plasmid chemokines and colony- ...... iciency virus type 1 vaccines.
@ast
Plasmid chemokines and colony- ...... iciency virus type 1 vaccines.
@en
prefLabel
Plasmid chemokines and colony- ...... iciency virus type 1 vaccines.
@ast
Plasmid chemokines and colony- ...... iciency virus type 1 vaccines.
@en
P2093
P2860
P1433
P1476
Plasmid chemokines and colony- ...... iciency virus type 1 vaccines.
@en
P2093
Bimal K Chakrabarti
Darci A Gorgone
Michelle A Lifton
Norman L Letvin
Paul F McKay
Sampa Santra
Shawn M Sumida
Shawn S Jackson
P2860
P304
P356
10.1128/JVI.77.16.8729-8735.2003
P407
P577
2003-08-01T00:00:00Z